Comparison of the Efficacy of Intravesical Bacillus Calmette-Guérin with Thiotepa, Mitomycin C, Poly I:C/Poly-L-Lysine and Cis Platinum in Murine Bladder Cancer

No AccessJournal of Urology1 Jan 1984Comparison of the Efficacy of Intravesical Bacillus Calmette-Guérin with Thiotepa, Mitomycin C, Poly I:C/Poly-L-Lysine and Cis Platinum in Murine Bladder Cancer Amos Shapiro, Timothy L. Ratliff, Dennis M. Oakley, and William J. Catalona Amos ShapiroAmos Shapiro Hadassah University Hospital, Jerusalem, Israel. More articles by this author , Timothy L. RatliffTimothy L. Ratliff More articles by this author , Dennis M. OakleyDennis M. Oakley More articles by this author , and William J. CatalonaWilliam J. Catalona More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)50246-3AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The efficacy of intravesical Bacillus Calmette-Guérin for the treatment of the mouse bladder tumor MBT-2 was compared with that of thiotepa, mitomycin C, cis-diamminedichloroplatinum II and poly I:C/poly-L-lysine. MBT-2 cells were instilled into the bladder immediately after electro-cauterization. Drug instillations were initiated 24 hours later and continued on a weekly basis for 4 weeks. Both Bacillus Calmette-Guérin and cis-diamminedichloroplatinum II significantly (p <.0004) inhibited MBT-2 tumor implantation when compared to diluent-treated controls. Neither mitomycin C, thiotepa nor poly I:C/poly-L-lysine significantly inhibited tumor implantation. Mean tumor weights also were significantly (p <.05) reduced in Bacillus Calmette-Guérin and cis-diamminedichloroplatinum II-treated mice, while tumor mean weights in mice treated with thiotepa, mitomycin C or poly hC/poly-L-lysine were not significantly different than controls. These results suggest that the efficacy of intravesical Bacillus Calmette-Guérin in comparison with other drugs in the MBT-2 mouse bladder tumor model is similar to observations reported in human clinical trials in which intravesical Bacillus Calmette-Guérin was shown to be more effective than other cytotoxic drugs. These data further support the utility of the MBT-2 model for the study of the mechanisms by which Bacillus Calmette-Guérin inhibits bladder tumor growth. © 1984 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByGUNTHER J, FRAMBACH M, DEINERT I, BRANDAU S, JOCHAM D and BOHLE A (2018) EFFECTS OF ACETYLIC SALICYLIC ACID AND PENTOXIFYLLINE ON THE EFFICACY OF INTRAVESICAL BCG THERAPY IN ORTHOTOPIC MURINE BLADDER CANCER (MB49)Journal of Urology, VOL. 161, NO. 5, (1702-1706), Online publication date: 1-May-1999.Pobe D, Horowitz A, Vlodavsky I, Shapiro A and Biran S (2018) Prevention of Human Bladder Tumor Cell Implantation in an in Vitro AssayJournal of Urology, VOL. 137, NO. 4, (777-781), Online publication date: 1-Apr-1987.Lee K, Weiss G, O’Donnell R and Cockett A (2018) Reduction of Bladder Cancer Growth in Mice Treated with Intravesical Bacillus Calmette Guerin and Systemic Interleukin 2Journal of Urology, VOL. 137, NO. 6, (1270-1273), Online publication date: 1-Jun-1987.Morales A and Pang A (2018) Prophylaxis and Therapy of an Experimental Bladder Cancer with Biological Response ModifiersJournal of Urology, VOL. 135, NO. 1, (191-193), Online publication date: 1-Jan-1986. Volume 131Issue 1January 1984Page: 139-142 Advertisement Copyright & Permissions© 1984 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Amos Shapiro Hadassah University Hospital, Jerusalem, Israel. More articles by this author Timothy L. Ratliff More articles by this author Dennis M. Oakley More articles by this author William J. Catalona More articles by this author Expand All Advertisement PDF DownloadLoading ...